Hamburg, Germany - Evotec Technologies GmbH (Evotec), a supplier of innovative tools and technologies for life sciences and pharmaceutical drug discovery, today announced the successful set-up of Evotec's ultra high throughput screening system in the Institut Pasteur Korea which will contribute to a strong forth quarter for the Company.
Evotec has delivered and successfully acceptance tested its uHTS system EVOscreen® as well as two high content imaging readers Opera(TM) in Korea. The combination of both platforms for industrial drug discovery allows high content analysis at ultra high-throughput. State-of-the-art, novel biochemical, cellular and whole organism assays can be run. EVOscreen® can perform assays down to 1 microlitre, providing unique advantages in compound saving and unrivalled data quality. It has been fully validated to run unattended, which qualifies this platform as the only uHTS system worldwide that may be operated in P3 security level laboratories.
"We are extremely proud to be the partner of choice of the Institut Pasteur Korea, a brand new life science research centre with outstanding biological expertise. The delivery of an EVOscreen® system is a cornerstone for Evotec Technologies since it is its first installation in Asia, and the first in an academic environment ever, giving us clear visibility of our products in the rapidly growing Asian market. It also demonstrates that EVOscreen® has become a very attractive tool for academia to adopt revolutionary, new experimental strategies," stated Dr Rolf Günther, CSO at Evotec Technologies GmbH.
About Evotec Technologies
Evotec Technologies GmbH (ET) is a subsidiary of Evotec OAI AG focussed on technology development and instrumentation for life sciences laboratories. The Company provides state-of-the-art automated and miniaturised processes that result in extremely high data content and quality output by seamlessly integrating hardware, software and bioware modules. ET's current portfolio comprises its established uHTS EVOscreen® system and a product line of innovative bench-top instruments (Opera(TM), Clarina II, Elektra), consumables and reagents. These solutions are based on its broad patent portfolio, scientific excellence - from drug discovery to diagnostics - and technical know-how. ET's particular strengths are in detection and analysis in molecular dimensions, liquid handling of minimal volumes and high-speed interpretation methods and software. Evotec Technologies employs 80 people, primarily at its main site in Hamburg, Germany. Offices are located in Düsseldorf, Berlin and Boston.
Contact: Anne Hennecke, Director Investor Relations & Corporate Communications, Evotec OAI AG, phone: +49-40-56081-286, anne.hennecke@evotecoai.com
Contact: Anne Hennecke, Director Investor Relations & Corporate Communications, Evotec OAI AG, phone: +49-40-56081-286, anne.hennecke@evotecoai.com
Evotec Technologies provides EVOscreen® and Opera to Korea
TOP